A phospholipid mimetic targeting LRH-1 ameliorates colitis

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Phospholipids act as ligands for nuclear hormone receptors (NHRs), influencing transcriptional programs in physiology and disease.
• Liver receptor homolog-1 (LRH-1) is a key NHR and a therapeutic target for inflammatory conditions like colitis.
• Current LRH-1 modulators have limitations, with incomplete binding pocket occupation and missed allosteric interactions.

Purpose of the Study:

• To develop improved LRH-1 agonists by mimicking natural phospholipid-NR interactions.
• To investigate the efficacy of phospholipid-mimetic molecules as potential therapeutics for colitis.

Main Methods:

• Design and synthesis of novel molecules incorporating phospholipid elements onto a synthetic LRH-1 agonist.
• Structural analysis using crystal structures to confirm interactions with target residues.
• Assessment of binding affinity, transcriptional activity, and allosteric modulation of LRH-1.
• Evaluation of therapeutic efficacy in a murine T cell transfer model of colitis.

Main Results:

• Phospholipid-mimicking groups successfully interacted with key residues in LRH-1, as confirmed by crystal structures.
• The novel molecules exhibited enhanced binding affinity and LRH-1 transcriptional activity compared to conventional modulators.
• Improved allosteric modulation at a critical site within the LRH-1 binding pocket was observed.
• The lead phospholipid mimetic significantly ameliorated colonic histopathology and weight loss in a colitis model.

Conclusions:

• Mimicking phospholipid-NR interactions is a viable strategy for enhancing LRH-1 agonist potency and efficacy.
• This approach represents a significant advancement in the development of LRH-1-based therapeutics for colitis.
• The demonstrated in vivo efficacy provides strong preclinical evidence for this novel therapeutic strategy.